Physician profile
Christopher Izzo
NPI 1053816355
$9,582.97
in general payments reported to CMS, 2019-2025
15 companies · $9,234 in 2025
The $9,234 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2024: $246 · 2025: $9,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Food and Beverage: $1,335 · Travel and Lodging: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Food and Beverage | $1,334.76 |
| Travel and Lodging | $1,145.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,179.18 | 2025 | |
| Pulmonx Corporation | $252.33 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Grifols Shared Services North America, INC. | $246.91 | 2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.63 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $179.65 | 2024-2025 | Tagrisso, Breztri, Tezspire |
| Insmed, INC. | $116.09 | 2025 | Arikayce |
| Glaxosmithkline, LLC. | $77.84 | 2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $74.97 | 2025 | |
| Merck Sharp & Dohme LLC | $62.60 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $58.57 | 2025 | Dupixent |
| United Therapeutics Corporation | $30.62 | 2025 | Tyvaso |
| Inogen, INC. | $27.13 | 2025 | |
| Verona Pharma, INC. | $21.74 | 2025 | Ohtuvayre |
| Amgen INC. | $14.91 | 2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $13.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Izzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.